The aim of this study was to explore perceptions about PCa risk and subsequent opportunistic screening among patients who were not at increased risk of PCa after a first normal PSA test with an average genetic lifetime risk assessment. The gene discussed is KLK3; the disease is posterior cortical atrophy.